The University of Chicago Header Logo

Connection

Co-Authors

This is a "connection" page, showing publications co-authored by Ralph R. Weichselbaum and Sean Pitroda.
Connection Strength

12.262
  1. Immunoradiotherapy goes club(bing). Nat Cancer. 2021 09; 2(9):871-872.
    View in: PubMed
    Score: 0.820
  2. Integrated molecular and clinical staging defines the spectrum of metastatic cancer. Nat Rev Clin Oncol. 2019 09; 16(9):581-588.
    View in: PubMed
    Score: 0.714
  3. Integration of radiotherapy and immunotherapy for treatment of oligometastases. Lancet Oncol. 2019 08; 20(8):e434-e442.
    View in: PubMed
    Score: 0.709
  4. Author Correction: Integrated molecular subtyping defines a curable oligometastatic state in colorectal liver metastasis. Nat Commun. 2018 11 13; 9(1):4827.
    View in: PubMed
    Score: 0.675
  5. Integrated molecular subtyping defines a curable oligometastatic state in colorectal liver metastasis. Nat Commun. 2018 05 04; 9(1):1793.
    View in: PubMed
    Score: 0.651
  6. Tumor endothelial inflammation predicts clinical outcome in diverse human cancers. PLoS One. 2012; 7(10):e46104.
    View in: PubMed
    Score: 0.442
  7. MUC1-induced alterations in a lipid metabolic gene network predict response of human breast cancers to tamoxifen treatment. Proc Natl Acad Sci U S A. 2009 Apr 07; 106(14):5837-41.
    View in: PubMed
    Score: 0.346
  8. Radiotherapy and immunology. J Exp Med. 2024 Jul 01; 221(7).
    View in: PubMed
    Score: 0.247
  9. Epitranscriptional regulation of TGF-ß pseudoreceptor BAMBI by m6A/YTHDF2 drives extrinsic radioresistance. J Clin Invest. 2023 Dec 15; 133(24).
    View in: PubMed
    Score: 0.240
  10. RNA m6A methylation and MDSCs: Roles and therapeutic implications for radiotherapy. Med. 2023 Dec 08; 4(12):863-874.
    View in: PubMed
    Score: 0.240
  11. YTHDF2 inhibition potentiates radiotherapy antitumor efficacy. Cancer Cell. 2023 07 10; 41(7):1294-1308.e8.
    View in: PubMed
    Score: 0.231
  12. Author Correction: Tumor aneuploidy predicts survival following immunotherapy across multiple cancers. Nat Genet. 2023 Feb; 55(2):355.
    View in: PubMed
    Score: 0.226
  13. Highly aneuploid non-small cell lung cancer shows enhanced responsiveness to concurrent radiation and immune checkpoint blockade. Nat Cancer. 2022 12; 3(12):1498-1512.
    View in: PubMed
    Score: 0.223
  14. Tumor aneuploidy predicts survival following immunotherapy across multiple cancers. Nat Genet. 2022 12; 54(12):1782-1785.
    View in: PubMed
    Score: 0.223
  15. A proliferative subtype of colorectal liver metastases exhibits hypersensitivity to cytotoxic chemotherapy. NPJ Precis Oncol. 2022 Oct 14; 6(1):72.
    View in: PubMed
    Score: 0.221
  16. Beyond the Visible Spectrum: Considering the Oligometastatic Hypothesis in the Light of a New Era. Int J Radiat Oncol Biol Phys. 2022 11 15; 114(4):581-586.
    View in: PubMed
    Score: 0.221
  17. The oligometastatic spectrum in the era of improved detection and modern systemic therapy. Nat Rev Clin Oncol. 2022 09; 19(9):585-599.
    View in: PubMed
    Score: 0.218
  18. Combined radio-immunotherapy: An opportunity to increase the therapeutic ratio of oligometastasis-directed radiotherapy. Neoplasia. 2022 05; 27:100782.
    View in: PubMed
    Score: 0.213
  19. Radiotherapy and immunotherapy: open questions and future strategies. Trends Cancer. 2022 01; 8(1):9-20.
    View in: PubMed
    Score: 0.207
  20. CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer. Sci Rep. 2021 10 08; 11(1):20059.
    View in: PubMed
    Score: 0.206
  21. Radiotherapy and Immunotherapy Combinations in the Treatment of Patients with Metastatic Disease: Current Status and Future Focus. Clin Cancer Res. 2021 10 01; 27(19):5188-5194.
    View in: PubMed
    Score: 0.206
  22. Treatment of Cancer with Radio-Immunotherapy: What We Currently Know and What the Future May Hold. Int J Mol Sci. 2021 Sep 03; 22(17).
    View in: PubMed
    Score: 0.205
  23. The Spectrum of Metastasis: An Opportunity for Cure? Semin Radiat Oncol. 2021 07; 31(3):174-179.
    View in: PubMed
    Score: 0.203
  24. Suppression of local type I interferon by gut microbiota-derived butyrate impairs antitumor effects of ionizing radiation. J Exp Med. 2021 03 01; 218(3).
    View in: PubMed
    Score: 0.198
  25. Radiotherapy and immunotherapy converge on elimination of tumor-promoting erythroid progenitor cells through adaptive immunity. Sci Transl Med. 2021 02 24; 13(582).
    View in: PubMed
    Score: 0.198
  26. (Oligo)metastasis as a Spectrum of Disease. Cancer Res. 2021 05 15; 81(10):2577-2583.
    View in: PubMed
    Score: 0.196
  27. Oligometastasis: Past, Present, Future. Int J Radiat Oncol Biol Phys. 2020 11 01; 108(3):530-538.
    View in: PubMed
    Score: 0.193
  28. Cytoreduction and the Optimization Of Immune Checkpoint Inhibition with Radiation Therapy. Int J Radiat Oncol Biol Phys. 2020 09 01; 108(1):17-26.
    View in: PubMed
    Score: 0.191
  29. Definition, Biology, and History of Oligometastatic and Oligoprogressive Disease. Cancer J. 2020 Mar/Apr; 26(2):96-99.
    View in: PubMed
    Score: 0.185
  30. Tumor-reprogrammed resident T cells resist radiation to control tumors. Nat Commun. 2019 09 02; 10(1):3959.
    View in: PubMed
    Score: 0.178
  31. Beyond Palliation: The Rationale for Metastasis-Directed Therapy for Metastatic Non-Small Cell Lung Cancer. J Thorac Oncol. 2019 09; 14(9):1510-1512.
    View in: PubMed
    Score: 0.176
  32. Staging the Metastatic Spectrum Through Integration of Clinical and Molecular Features. J Clin Oncol. 2019 05 20; 37(15):1270-1276.
    View in: PubMed
    Score: 0.173
  33. Oligometastatic prostate cancer: Reality or figment of imagination? Cancer. 2019 02 01; 125(3):340-352.
    View in: PubMed
    Score: 0.170
  34. JAK2 Inhibitor SAR302503 Abrogates PD-L1 Expression and Targets Therapy-Resistant Non-small Cell Lung Cancers. Mol Cancer Ther. 2018 04; 17(4):732-739.
    View in: PubMed
    Score: 0.161
  35. Low Recombination Proficiency Score (RPS) Predicts Heightened Sensitivity to DNA-Damaging Chemotherapy in Breast Cancer. Clin Cancer Res. 2017 Aug 01; 23(15):4493-4500.
    View in: PubMed
    Score: 0.151
  36. Ad.Egr-TNF and Local Ionizing Radiation Suppress Metastases by Interferon-ß-Dependent Activation of Antigen-specific CD8+ T Cells. Mol Ther. 2010 May; 18(5):912-920.
    View in: PubMed
    Score: 0.148
  37. Basal Tumor Cell Isolation and Patient-Derived Xenograft Engraftment Identify High-Risk Clinical Bladder Cancers. Sci Rep. 2016 10 24; 6:35854.
    View in: PubMed
    Score: 0.146
  38. microRNAs and oligometastasis. Aging (Albany NY). 2015 Mar; 7(3):146-7.
    View in: PubMed
    Score: 0.131
  39. 14q32-encoded microRNAs mediate an oligometastatic phenotype. Oncotarget. 2015 Feb 28; 6(6):3540-52.
    View in: PubMed
    Score: 0.131
  40. DNA repair pathway gene expression score correlates with repair proficiency and tumor sensitivity to chemotherapy. Sci Transl Med. 2014 Mar 26; 6(229):229ra42.
    View in: PubMed
    Score: 0.122
  41. MUC1-associated proliferation signature predicts outcomes in lung adenocarcinoma patients. BMC Med Genomics. 2010 May 06; 3:16.
    View in: PubMed
    Score: 0.093
  42. Ad.Egr-TNF and local ionizing radiation suppress metastases by interferon-beta-dependent activation of antigen-specific CD8+ T cells. Mol Ther. 2010 May; 18(5):912-20.
    View in: PubMed
    Score: 0.092
  43. STAT1-dependent expression of energy metabolic pathways links tumour growth and radioresistance to the Warburg effect. BMC Med. 2009 Nov 05; 7:68.
    View in: PubMed
    Score: 0.090
  44. STAT1 pathway mediates amplification of metastatic potential and resistance to therapy. PLoS One. 2009 Jun 08; 4(6):e5821.
    View in: PubMed
    Score: 0.088
  45. MUC1-induced transcriptional programs associated with tumorigenesis predict outcome in breast and lung cancer. Cancer Res. 2009 Apr 01; 69(7):2833-7.
    View in: PubMed
    Score: 0.087
  46. Translational strategies exploiting TNF-alpha that sensitize tumors to radiation therapy. Cancer Gene Ther. 2009 Apr; 16(4):373-81.
    View in: PubMed
    Score: 0.084
  47. Radiotherapy Enhances Metastasis Through Immune Suppression by Inducing PD-L1 and MDSC in Distal Sites. Clin Cancer Res. 2024 May 01; 30(9):1945-1958.
    View in: PubMed
    Score: 0.062
  48. Integrated Clinical-Molecular Classification of Colorectal Liver Metastases: A Biomarker Analysis of the Phase 3 New EPOC Randomized Clinical Trial. JAMA Oncol. 2023 09 01; 9(9):1245-1254.
    View in: PubMed
    Score: 0.059
  49. Oligometastases: Characterizing the Role of Epigenetic Regulation of Epithelial-Mesenchymal Transition. Clin Cancer Res. 2023 08 01; 29(15):2761-2766.
    View in: PubMed
    Score: 0.059
  50. Updates on radiotherapy-immunotherapy combinations: Proceedings of 6th annual ImmunoRad conference. Oncoimmunology. 2023; 12(1):2222560.
    View in: PubMed
    Score: 0.058
  51. ASO Visual Abstract: Phase II Prospective Open-Label Randomized Controlled Trial Comparing Standard of Care Chemotherapy with and without Sequential Cytoreductive Interventions for Patients with Oligometastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels. Ann Surg Oncol. 2022 Dec; 29(Suppl 3):616-617.
    View in: PubMed
    Score: 0.056
  52. Loss of MEN1 function impairs DNA repair capability of pancreatic neuroendocrine tumors. Endocr Relat Cancer. 2022 03 21; 29(4):225-239.
    View in: PubMed
    Score: 0.053
  53. Phase II Prospective, Open-Label Randomized Controlled Trial Comparing Standard of Care Chemotherapy With and Without Sequential Cytoreductive Interventions for Patients with Oligometastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor Deoxyribose Nucleic Acid (ctDNA) Levels. Ann Surg Oncol. 2022 Jan 05.
    View in: PubMed
    Score: 0.052
  54. Evaluation of Initial Metastatic Tumor Location and Radiation Response to Determine Outcomes in Patients Who Received Combination Stereotactic Body Radiotherapy and Immunotherapy for NSCLC. Int J Radiat Oncol Biol Phys. 2021 Nov 01; 111(3S):e449.
    View in: PubMed
    Score: 0.052
  55. A Phase 1 Trial of Concurrent or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients With Stage IV NSCLC Study. J Thorac Oncol. 2022 01; 17(1):130-140.
    View in: PubMed
    Score: 0.051
  56. Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors. Clin Cancer Res. 2021 10 15; 27(20):5510-5518.
    View in: PubMed
    Score: 0.051
  57. Improved Survival Associated with Local Tumor Response Following Multisite Radiotherapy and Pembrolizumab: Secondary Analysis of a Phase I Trial. Clin Cancer Res. 2020 12 15; 26(24):6437-6444.
    View in: PubMed
    Score: 0.048
  58. DNA Methylation Controls Metastasis-Suppressive 14q32-Encoded miRNAs. Cancer Res. 2019 02 01; 79(3):650-662.
    View in: PubMed
    Score: 0.042
  59. Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors. J Clin Oncol. 2018 06 01; 36(16):1611-1618.
    View in: PubMed
    Score: 0.040
  60. Advanced Animal Model of Colorectal Metastasis in Liver: Imaging Techniques and Properties of Metastatic Clones. J Vis Exp. 2016 11 30; (117).
    View in: PubMed
    Score: 0.037
  61. Clinical and molecular markers of long-term survival after oligometastasis-directed stereotactic body radiotherapy (SBRT). Cancer. 2016 07 15; 122(14):2242-50.
    View in: PubMed
    Score: 0.036
  62. Cancer therapies activate RIG-I-like receptor pathway through endogenous non-coding RNAs. Oncotarget. 2016 May 03; 7(18):26496-515.
    View in: PubMed
    Score: 0.035
  63. Imaging of tumor clones with differential liver colonization. Sci Rep. 2015 Jun 22; 5:10946.
    View in: PubMed
    Score: 0.033
  64. Oncogenic CXCL10 signalling drives metastasis development and poor clinical outcome. Br J Cancer. 2015 Jul 14; 113(2):327-35.
    View in: PubMed
    Score: 0.033
  65. MUC1-C activates the TAK1 inflammatory pathway in colon cancer. Oncogene. 2015 Oct 01; 34(40):5187-97.
    View in: PubMed
    Score: 0.033
  66. RIG-I-like receptor LGP2 protects tumor cells from ionizing radiation. Proc Natl Acad Sci U S A. 2014 Jan 28; 111(4):E484-91.
    View in: PubMed
    Score: 0.030
  67. Cooperative interaction between the MUC1-C oncoprotein and the Rab31 GTPase in estrogen receptor-positive breast cancer cells. PLoS One. 2012; 7(7):e39432.
    View in: PubMed
    Score: 0.027
  68. Cooperativity of the MUC1 oncoprotein and STAT1 pathway in poor prognosis human breast cancer. Oncogene. 2010 Feb 11; 29(6):920-9.
    View in: PubMed
    Score: 0.023
  69. Radioresistance of Stat1 over-expressing tumour cells is associated with suppressed apoptotic response to cytotoxic agents and increased IL6-IL8 signalling. Int J Radiat Biol. 2009 May; 85(5):421-31.
    View in: PubMed
    Score: 0.022
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.